AstraZeneca: Head and Neck Neoplasms trials
The registry lists 17 Head and Neck Neoplasms studies with AstraZeneca as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 1 6Phase 2 9Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerActive, not recruitingNCT04590963Phase 3Results posted
- Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results posted
- Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck CancerCompletedNCT02369874Phase 3Results posted
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and NeckCompletedNCT02319044Phase 2Results posted
- Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02207530Phase 2Results posted
- The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck CancerCompletedNCT00243347Phase 1Results posted
- First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
- An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckApproved for marketingNCT00684385
- Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck CancerCompletedNCT00681967Phase 1
- The IRESSA Novel Head and Neck Chemotherapy Evaluation StudyCompletedNCT00255476Phase 2
- ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck CancerCompletedNCT00242762Phase 2
- IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck CarcinomaCompletedNCT00242749Phase 2
- Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck CancerCompletedNCT00239304Phase 1/2
- Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT00233636Phase 2
- Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck CarcinomaCompletedNCT00228488Phase 2